Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Biomaterial research

Parkinson's disease: hydrogel and acupuncture approach shows promise

A biodegradable, electroconductive self-healing hydrogel combined with acupuncture could help restore motor function and protect brain neurons in Parkinson’s disease models.

News • Research on Antrodia cinnamomea

Promising fungal compound to fight cancer and inflammation

Studies have found that natural polysaccharides from a medical fungus endemic to Taiwan can not only effectively inhibit inflammation, but also fight the proliferation of lung cancer cells.

Article • On the hunt for skilled personnel

Staff shortage in the medical lab: solutions for a growing challenge

Shortages of skilled staff is creating challenges in medical laboratories across Europe. Many workers are nearing retirement age with numerous hospital laboratories having unfilled positions and…